Innovative Applications and R&D Drive the Respiratory Disease Testing Market Growth

Global respiratory disease testing market is anticipated to grow at a considerable CAGR of 6.3% during the forecast period (2024-2031). The global respiratory disease testing market uses various applications to diagnose and monitor respiratory conditions. Common applications include diagnosing respiratory infections, screening for chronic diseases, assessing lung cancer risk, monitoring respiratory function in critical care, evaluating allergic respiratory conditions, and assessing occupational lung diseases. Tests such as PCR, antigen detection assays, and culture-based methods are used to identify respiratory pathogens. Lung function tests, such as spirometry and FeNO, are used to assess lung function and identify abnormalities. Lung cancer risk is assessed using low-dose CT scanning, sputum cytology, and molecular biomarker analysis. Monitoring respiratory function in critical care is essential for managing allergic conditions and assessing occupational lung diseases caused by occupational hazards. Furthermore, the market has seen significant growth primarily owing to increased focus on R&D by both public and private organizations and growing applications. For instance,

Browse the full report description of “Respiratory Disease Testing Market Size, Share & Trends Analysis Report by Product and Service (Instruments & Devices, Assays & Reagents, and Services & Software). by Test Type (Imaging Tests, Mechanical Tests, and In-vitro Diagnostic Tests). by Disease Indication (Tuberculosis, Asthma, Lung Cancer, Chronic Obstructive Pulmonary Disease, and Others). and by End Users (Hospitals and Clinics, Diagnostics Laboratories, and Others). Forecast Period (2024-2031).” at https://www.omrglobal.com/industry-reports/respiratory-disease-testing-market

In April 2023, the VitaloPFT Series, launched at the Arab Health Exhibition in Dubai, offers advanced respiratory diagnostic solutions for complex pulmonary function testing in hospitals and secondary care units, supported by Irish minister Dara Calleary TD and Irish ambassador Alison Milton.

In April 2023, QIAGEN launched its QIAstat-Dx syndromic testing solution in Japan, featuring a SARS-CoV-2 Respiratory Panel capable of detecting over 20 pathogens from a single patient sample, in mid-2023, following reimbursement decisions and IVD approval. This will expand QIAstat-Dx's global presence.

In November 2021, Cipla launched the Spirofy wireless device in India, a portable device capable of performing lung function tests outdoors and in remote areas to improve diagnosis of COPD and asthma in the country.

The market number available for – 2023-2031

• Base year- 2023

• Forecast period- 2024-2031

• Segment Covered- 

o By Product and Service

o By Test Type

o By Disease Indication

o By End User

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape-  Abbott Laboratories, Becton, Dickinson, and Co., Koninklijke Philips N.V., Merck KGaA, and Siemens Healthineers AG, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Respiratory Disease Testing Market Report Segment

By Product and Service

• Instruments & Devices
• Assays & Reagents
• Services & Software

By Test Type

• Imaging Tests   
• Mechanical Tests   
• In-vitro Diagnostic Tests

By Disease Indication

• Tuberculosis
• Asthma
• Lung Cancer
• Chronic Obstructive Pulmonary Disease
• Others (Interstitial Lung Disease (ILD), and Sleep Apnea)

By End-User

• Hospitals and Clinics
• Diagnostics Laboratories
• Others (Ambulatory Care Centers, and Government Health Agencies)

Global Respiratory Disease Testing Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/respiratory-disease-testing-market